Overview
Pharmaceutical Regulatory Affairs Training is the specialized education that prepares professionals to navigate the complex landscape of drug development and regulatory submissions. Regulatory affairs is a critical function in the pharmaceutical industry, serving as the bridge between drug developers and regulatory authorities such as the FDA, EMA, and other global agencies. This training covers the entire drug development lifecycle, from discovery through post-approval lifecycle management, and provides the knowledge needed to prepare and submit regulatory applications, interact with regulatory agencies, and maintain compliance.
https://www.gxptrainings.com/course-category/quality-regulatory
Why Pharmaceutical Regulatory Affairs Training Matters
Pharmaceutical Regulatory Affairs Training is essential for several critical reasons. The regulatory landscape is complex and constantly evolving, requiring professionals to stay current with changing requirements and best practices.
Regulatory Compliance – Regulatory affairs professionals ensure that drug development programs comply with applicable laws, regulations, and guidance documents. This is essential for obtaining and maintaining marketing approval.
Submission Preparation – Regulatory affairs professionals prepare and submit regulatory applications, including INDs, NDAs, BLAs, and ANDAs. This requires specialized knowledge of submission formats, content requirements, and regulatory expectations.
Agency Interactions – Regulatory affairs professionals interact with regulatory agencies throughout the drug development lifecycle. This includes meetings, correspondence, and negotiations.
Patient Safety – Regulatory affairs ensures that drugs are safe and effective by guiding development programs and ensuring that data are collected and submitted in a manner that supports regulatory decision-making.
Key Regulatory Submissions Covered
Pharmaceutical Regulatory Affairs Training covers the full spectrum of regulatory submissions, including:
Investigational New Drug (IND) Applications – IND applications are submitted to the FDA to authorize clinical trials. Training covers the content and format of IND submissions, including chemistry, manufacturing, and controls (CMC), nonclinical pharmacology and toxicology, and clinical protocols.
New Drug Applications (NDA) – NDAs are submitted to obtain marketing approval for new drugs. Training covers the full NDA submission, organized into the five CTD modules, including CMC, nonclinical, clinical, and statistical sections.
Biologics License Applications (BLA) – BLAs are submitted for biological products. Training covers the legal and statutory basis for BLAs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
Abbreviated New Drug Applications (ANDA) – ANDAs are submitted for generic drugs. Training covers the Hatch-Waxman Act, bioequivalence studies, patent certification, and FDA review processes.
Orphan Drug Designation – Orphan drug designation is granted to drugs intended for the treatment of rare diseases. Training covers the Orphan Drug Act, the designation process, and the benefits including seven-year market exclusivity.
Who Needs Pharmaceutical Regulatory Affairs Training?
Pharmaceutical Regulatory Affairs Training is required for a wide range of professionals involved in drug development and regulatory submissions.
Regulatory Affairs Professionals – Associates, managers, directors, strategy specialists, and submission managers need comprehensive training to perform their roles effectively.
Pharmaceutical Development Scientists – Formulation scientists, product development managers, and scale-up specialists need to understand regulatory requirements for CMC sections.
Quality Assurance/Quality Control Professionals – QA/QC professionals need to understand regulatory expectations for data integrity, CGMP compliance, and inspection readiness.
Clinical and Nonclinical Development Professionals – Clinical pharmacologists, bioequivalence study managers, and nonclinical scientists need to understand the regulatory context of their work.
CMC Specialists and Manufacturing Personnel – CMC regulatory affairs specialists, analytical development scientists, and manufacturing personnel need to understand submission requirements.
Project Management Professionals – Project managers coordinating cross-functional submission teams need regulatory knowledge to manage timelines and resources effectively.
Legal and Intellectual Property Professionals – Patent attorneys and intellectual property counsel need to understand regulatory strategy for patent certification and exclusivity.
Detailed Course Breakdown
Course 1: Certified Regulatory Affairs Professional (CRAP)
This comprehensive certification program provides regulatory professionals with end-to-end knowledge of the global pharmaceutical regulatory landscape. The program covers the complete drug development lifecycle from discovery through post-approval lifecycle management, with specific focus on the regulatory requirements of the United States (FDA), European Union (EMA), and Japan (PMDA), as well as harmonization initiatives under ICH.
Scope: The program is structured to provide both foundational regulatory knowledge and advanced strategic capabilities across all major application types, including Investigational New Drug (IND) applications, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Biologics License Applications (BLA), Orphan Drug Designation, and Special Programs including Accelerated Approval, Breakthrough Therapy, and Priority Review.
Description of Modules: The curriculum covers:
- Global Regulatory Framework – statutory and regulatory authorities in the US, EU, and Japan
- Drug Approval Pathway – from discovery through post-approval lifecycle management
- Investigational New Drug (IND) applications
- New Drug Applications (NDA) for innovative pharmaceuticals
- Abbreviated New Drug Applications (ANDA) for generic drugs
- Biologics License Applications (BLA) for biological products
- Orphan Drug Designation for rare disease treatments
- Special Programs including Accelerated Approval, Breakthrough Therapy, and Priority Review
- Post-approval lifecycle management – SUPAC requirements, annual reports, and postmarketing safety surveillance
- Regulatory agency interactions – formal meetings, controlled correspondence, and meeting management
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) Personnel
- Legal and Intellectual Property Professionals
Pricing: $799.00 with group discounts available.
FAQ:
- What is the difference between an IND and an NDA? An IND (Investigational New Drug) application is submitted to authorize clinical trials, while an NDA (New Drug Application) is submitted to obtain marketing approval for a new drug.
- What is the eCTD format? eCTD (Electronic Common Technical Document) is the standard format for regulatory submissions, enabling efficient review and global harmonization.
- What is the purpose of an Orphan Drug Designation? Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases, providing incentives such as market exclusivity and tax credits.
- What is the role of ICH in global drug development? ICH develops guidelines that harmonize regulatory requirements across regions, facilitating efficient global drug development.
- What are the key elements of a Biologics License Application (BLA)? A BLA includes manufacturing information, nonclinical studies, clinical data, and labeling for biological products.
Enroll Now: https://www.gxptrainings.com/courses/certified-regulatory-affairs-professional/
Course 2: Biologics License Application (BLA) Certification
This certification program provides regulatory professionals with comprehensive knowledge of the planning, preparation, submission, review, and lifecycle management of Biologics License Applications (BLAs) submitted to the U.S. Food and Drug Administration (FDA).
Scope: This program encompasses the complete regulatory framework governing biologics from initial discovery through post-approval lifecycle management. Participants will learn the legal and statutory basis for BLAs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. The program covers the full eCTD submission structure from Module 1 through Module 5, including administrative information, quality summaries, CMC data for drug substance and drug product, nonclinical study reports, and clinical study reports. Additional focus areas include facility inspections, pre-license inspections, process validation, stability programs, viral safety, immunogenicity, clinical pharmacology, biostatistics, and post-approval change management.
Description of Modules: The curriculum covers:
- Regulatory foundation – PHS Act, FD&C Act, 21 CFR Parts 600, 601, 610, 210, 211
- Development lifecycle – Discovery research through post-approval
- eCTD submission – Modules 1 through 5 structure and content
- CMC – Drug substance, drug product, process validation, stability, viral safety
- Nonclinical studies – Pharmacology, toxicology, pharmacokinetics, immunogenicity
- Clinical studies – Phase 1-3 design, safety, efficacy, biostatistics
- FDA review process – Filing, mid-cycle, late-cycle, advisory committee
- Inspections – Pre-license, facility, inspection readiness
- Post-approval – Supplements, annual reports, post-marketing requirements, change control
- Special programs – Accelerated approval, breakthrough therapy, orphan designation, pediatric studies
Target Audience:
- Regulatory Affairs Professionals
- CMC Scientists and Technical Writers
- Quality Assurance and Quality Control Personnel
- Manufacturing Personnel (bioprocess, fill/finish, quality operations)
- Clinical Development Teams (physicians, clinical scientists, project managers)
- Nonclinical Scientists (pharmacology, toxicology, pharmacokinetics)
- Pharmacovigilance Professionals
- Regulatory Project Managers
- Medical Writers
- Biotechnology Executives
- Regulatory Consultants
- Auditors and Inspectors
Pricing: $499.00 with group discounts available.
FAQ:
- What is the difference between a BLA and an NDA? A BLA (Biologics License Application) is submitted for biological products such as vaccines, gene therapies, and monoclonal antibodies, while an NDA is submitted for conventional small molecule drugs.
- What is the Public Health Service Act? The Public Health Service Act provides the statutory authority for the regulation of biological products, including the requirement for a BLA.
- What are 21 CFR Parts 600, 601, and 610? These regulations cover the requirements for biologics licensing, including manufacturing, testing, and labeling of biological products.
- What is a pre-license inspection? A pre-license inspection is an FDA inspection of the manufacturing facility before a BLA is approved to ensure compliance with GMP requirements.
- What is the role of CMC in a BLA? CMC (Chemistry, Manufacturing, and Controls) sections of a BLA provide detailed information about the drug substance, drug product, manufacturing process, and stability data.
Enroll Now: https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/
Course 3: ANDA Regulatory Affairs Certification
This comprehensive training program is designed to provide pharmaceutical professionals with an in-depth understanding of the regulatory requirements, scientific principles, and practical strategies for preparing and submitting Abbreviated New Drug Applications (ANDAs) to the U.S. Food and Drug Administration (FDA). The program incorporates the latest regulatory developments under the Generic Drug User Fee Amendments (GDUFA III), covering fiscal years 2023-2027, and reflects FDA’s current thinking on generic drug development and approval pathways as of June 2026.
Scope: The program covers the full spectrum of ANDA-related topics, from foundational regulatory knowledge to advanced strategic considerations. The scope includes regulatory framework, Orange Book and Reference Listed Drug selection, bioequivalence science and study design, Chemistry, Manufacturing, and Controls (CMC), labeling requirements, patent certification and exclusivity, Pre-ANDA and FDA engagement, post-approval changes and lifecycle management, data integrity and quality metrics, and complex generic products.
Description of Modules: The curriculum covers:
- Regulatory Framework – Hatch-Waxman Act, Section 505(j), GDUFA III
- Orange Book and RLD Selection – therapeutic equivalence codes, patent and exclusivity information
- Bioequivalence Science – pharmacokinetic principles, study design, statistical approaches, BCS-based biowaivers
- CMC – drug substance characterization, drug product formulation, stability studies, Drug Master Files
- Labeling Requirements – “same as” standard, prescribing information, patient labeling
- Patent Certification and Exclusivity – Paragraphs I-IV, 180-day exclusivity, litigation and 30-month stays
- Pre-ANDA and FDA Engagement – controlled correspondence, Pre-ANDA meetings, Product-Specific Guidance meetings
- Post-Approval Changes – SUPAC-IR, SUPAC-MR, reporting categories, supplements
- Data Integrity and Quality Metrics – ALCOA principles, CGMP requirements, audit trail review
- Complex Generic Products – drug-device combination products, human factors studies, complex formulations
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical Pharmacology and Bioequivalence Specialists
- Chemistry, Manufacturing, and Controls (CMC) Specialists
- Project Management Professionals
- Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) Personnel
- Legal and Intellectual Property Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is an ANDA? An Abbreviated New Drug Application (ANDA) is a submission to the FDA for approval of a generic drug product that is bioequivalent to an approved Reference Listed Drug.
- What is the Hatch-Waxman Act? The Hatch-Waxman Act established the framework for generic drug approvals, including the ANDA process, bioequivalence requirements, and patent certification provisions.
- What is a Paragraph IV certification? A Paragraph IV certification is a patent certification that the generic product does not infringe the RLD’s patents or that the patents are invalid, triggering notice to the patent holder and potential litigation.
- What is the 180-day exclusivity provision? 180-day exclusivity is a period of market exclusivity for the first generic applicant to file a Paragraph IV certification, providing an incentive for early generic entry.
- What is a bioequivalence study? A bioequivalence study demonstrates that the generic product delivers the same amount of active ingredient into the bloodstream as the Reference Listed Drug, with comparable rate and extent of absorption.
Enroll Now: https://www.gxptrainings.com/courses/anda-compliance-and-regulatory-training/
Course 4: New Drug Applications (NDA) Certification
This training program covers the entire drug development and approval process from discovery through post-approval lifecycle management. You will learn the complete drug approval pathway, then dive deep into each component of the New Drug Application (NDA) organized into the five CTD modules.
Scope: The program covers the complete drug approval pathway from discovery to post-approval. Case studies are integrated throughout for oral solid (tablets), parenteral (injectable vials), and oral solution (liquid) dosage forms. Participants will learn to prepare and submit a complete NDA organized into the five CTD modules.
Description of Modules: The curriculum covers:
- Drug Approval Pathway – from discovery to post-approval
- CTD Module 1 – Administrative and prescribing information
- CTD Module 2 – Summaries (quality overall summary, nonclinical overview, clinical overview)
- CTD Module 3 – Quality (CMC) sections for different dosage forms
- CTD Module 4 – Nonclinical study reports
- CTD Module 5 – Clinical study reports
- Clinical Trial Design – Phase 1-3, safety, efficacy, biostatistics
- Nonclinical Studies – Pharmacology, toxicology, pharmacokinetics
- CMC – Drug substance, drug product, stability, and manufacturing
- Post-Approval Changes – SUPAC requirements, annual reports, labeling updates
Target Audience:
- Regulatory Affairs Specialists and Associates
- Clinical Research Associates
- Medical Writers
- CMC Associates and Managers
- Nonclinical Scientists
- Quality Assurance Professionals
- Project Managers
- Compliance Officers
- Legal and Patent Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is a New Drug Application (NDA)? An NDA is a submission to the FDA requesting approval to market a new drug for human use.
- What is the CTD format? The CTD (Common Technical Document) is an internationally harmonized format for regulatory submissions, organized into five modules.
- What are the five CTD modules? Module 1 (Administrative), Module 2 (Summaries), Module 3 (Quality), Module 4 (Nonclinical), and Module 5 (Clinical).
- What is the difference between Phase 2 and Phase 3 studies? Phase 2 studies are dose-finding and preliminary efficacy, while Phase 3 studies are large, pivotal studies that provide the primary evidence of efficacy and safety.
- What is a Risk Evaluation and Mitigation Strategy (REMS)? A REMS is a strategy to manage known or potential serious risks associated with a drug product.
Enroll Now: https://www.gxptrainings.com/courses/mastering-the-nda/
Course 5: Orphan Drug NDA Certification
This training program covers the entire orphan drug development and approval process from rare disease discovery through preclinical development, clinical trials, NDA submission and FDA review, and post-approval lifecycle management including maintenance of seven-year orphan drug exclusivity. A fictional gene therapy for Duchenne Muscular Dystrophy is used as a running case study.
Scope: The program covers the Orphan Drug Act of 1983, the step-by-step process for obtaining orphan drug designation from the FDA Office of Orphan Products Development, the full range of benefits including seven-year market exclusivity, fifty percent tax credits, PDUFA fee waivers, and grant funding. The program then dives deeply into each component of the New Drug Application organized into the five CTD modules, with specific adaptations and flexibilities for orphan drug products.
Description of Modules: The curriculum covers:
- Orphan Drug Act – legal framework, history, and amendments
- Orphan Drug Designation – requesting designation from the Office of Orphan Products Development
- Rare Disease Drug Development – challenges and strategies for small patient populations
- Clinical Trials for Orphan Drugs – natural history studies, single arm trials, surrogate endpoints
- Accelerated Approval Pathways – validated surrogate endpoints and confirmatory trials
- NDA Preparation for Rare Disease Drugs – unique considerations and flexibilities
- Seven-Year Exclusivity – maintenance and annual reporting requirements
- Post-Approval Requirements – confirmatory trials, REMS, postmarketing surveillance
- FDA Review Process – filing, review, and approval considerations for orphan drugs
Target Audience:
- Regulatory Affairs Specialists working on gene therapies, enzyme replacement therapies, and other orphan products
- Clinical Research Associates conducting trials in rare disease populations
- Medical Writers preparing orphan drug designation requests
- CMC Associates for biologics and gene therapies
- Nonclinical Scientists working with rare disease animal models
- Quality Assurance Professionals for small batch manufacturing
- Project Managers for orphan drug development programs
- Legal and Patent Professionals for orphan drug exclusivity strategies
- Patient Advocacy Group Liaisons
Pricing: $499.00 with group discounts available.
FAQ:
- What is the Orphan Drug Act? The Orphan Drug Act of 1983 provides incentives for the development of drugs for rare diseases affecting fewer than 200,000 people in the US.
- What is orphan drug designation? Orphan drug designation is a special status granted by the FDA to drugs intended for the treatment of rare diseases, providing benefits including seven-year market exclusivity.
- What are the benefits of orphan drug designation? Benefits include seven-year market exclusivity, fifty percent tax credits for clinical trial costs, PDUFA fee waivers, and grant funding.
- What is the Office of Orphan Products Development? The Office of Orphan Products Development is the FDA office responsible for reviewing orphan drug designation requests and providing guidance for rare disease drug development.
- What are the unique considerations for orphan drug NDA submissions? Orphan drug NDAs may have small batch manufacturing, single arm clinical trials, natural history controls, surrogate endpoints, and accelerated approval pathways.
Enroll Now: https://www.gxptrainings.com/courses/mastering-the-orphan-drug-nda/
Course 6: GCP Global Auditor Certification
This training program defines the complete knowledge and performance requirements for personnel involved in clinical research to become certified global auditors for Good Clinical Practice (GCP) . The program integrates GCP requirements from ICH E6(R3), Health Canada Part C, Division 5 of the Food and Drug Regulations, and FDA regulations (21 CFR Parts 50, 56, 312, 314.50, and 314.80) with auditing practices based on ISO 19011:2026 for internal, second-party (vendor/CRO/site audits), and global regulatory compliance auditing.
Scope: The participant learns what GCP requires under multiple regulatory frameworks, how to audit those requirements, and how to conduct audits across multiple jurisdictions and organizational boundaries. The program covers informed consent processes, Institutional Review Board operations, Investigational New Drug applications, New Drug Applications, postmarketing safety reporting, investigator and sponsor responsibilities, and essential records.
Description of Modules: The curriculum covers:
- Regulatory Frameworks – ICH E6(R3), Health Canada Division 5, FDA 21 CFR Parts 50, 56, 312, 314
- Auditing Practices – seven principles of auditing, audit programme management, conducting audits, remote auditing methods
- Informed consent processes – compliance with 21 CFR Part 50 and ICH E6
- Institutional Review Board operations – composition, functions, and recordkeeping
- Investigational New Drug applications – content, safety reporting, and protocol compliance
- New Drug Applications – content, format, and technical sections
- Postmarketing safety reporting – compliance with 314.80 requirements
- Investigator responsibilities – qualifications, delegation, and oversight
- Sponsor responsibilities – quality systems, monitoring, and auditing
- Audit planning, execution, reporting, CAPA, and closure
Target Audience:
- Quality Assurance Personnel
- Clinical Research Associates (Monitors)
- Study Directors and Clinical Trial Managers
- Clinical Investigators and Site Staff
- Sponsor Personnel
- CRO Personnel
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Audit Program Managers
Pricing: $499.00 with group discounts available.
FAQ:
- What is GCP Global Auditor Certification? It is a certification that validates expertise in conducting GCP audits across multiple regulatory frameworks, including ICH E6(R3), Health Canada Division 5, and FDA regulations.
- What are the prerequisites for this certification? Completion of basic GCP awareness training and at least six months of experience in clinical research.
- What is ISO 19011:2026? ISO 19011:2026 provides guidelines for auditing management systems, covering audit principles, programme management, conduct, remote methods, and competence evaluation.
- What are the seven principles of auditing? The seven principles are integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- Can I conduct regulatory inspections with this certification? No, the program is designed for global auditing across internal, second-party, and regulatory readiness contexts and does not qualify individuals to conduct regulatory inspections on behalf of authorities.
Enroll Now: https://www.gxptrainings.com/courses/gcp-global-auditor-certification-program/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Authors
